J. Miceli

574 total citations
26 papers, 442 citations indexed

About

J. Miceli is a scholar working on Psychiatry and Mental health, Pharmacology and Pediatrics, Perinatology and Child Health. According to data from OpenAlex, J. Miceli has authored 26 papers receiving a total of 442 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Psychiatry and Mental health, 7 papers in Pharmacology and 6 papers in Pediatrics, Perinatology and Child Health. Recurrent topics in J. Miceli's work include Schizophrenia research and treatment (8 papers), Pharmacogenetics and Drug Metabolism (7 papers) and Epilepsy research and treatment (7 papers). J. Miceli is often cited by papers focused on Schizophrenia research and treatment (8 papers), Pharmacogenetics and Drug Metabolism (7 papers) and Epilepsy research and treatment (7 papers). J. Miceli collaborates with scholars based in United States, United Kingdom and Germany. J. Miceli's co-authors include Angélique Laurent, Chandra Prakash, Donghui Cui, Amin Kamel, Donald Tweedie, Keith D. Wilner, Richard Anziano, Glen Apseloff, Nicolas Gerber and Michael K. Smith and has published in prestigious journals such as Biological Psychiatry, Journal of Pharmacology and Experimental Therapeutics and Clinical Pharmacology & Therapeutics.

In The Last Decade

J. Miceli

25 papers receiving 407 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
J. Miceli United States 9 280 116 104 47 43 26 442
Cara L. Alfaro United States 7 160 0.6× 162 1.4× 91 0.9× 37 0.8× 59 1.4× 10 368
Sandra Boom United States 13 315 1.1× 61 0.5× 116 1.1× 52 1.1× 114 2.7× 22 517
Per T. Thyrum United States 14 340 1.2× 90 0.8× 98 0.9× 108 2.3× 130 3.0× 30 714
Aldo Madia Italy 10 533 1.9× 189 1.6× 142 1.4× 46 1.0× 162 3.8× 10 658
John W. Barnhill United States 8 128 0.5× 182 1.6× 66 0.6× 36 0.8× 62 1.4× 14 395
Katrin M. Kirschbaum Germany 13 204 0.7× 79 0.7× 116 1.1× 68 1.4× 80 1.9× 19 511
Krishna Talluri United States 12 371 1.3× 36 0.3× 113 1.1× 24 0.5× 79 1.8× 24 521
M. Ancione Italy 12 512 1.8× 180 1.6× 92 0.9× 57 1.2× 183 4.3× 13 661
E Jaquenoud Sirot Switzerland 7 196 0.7× 151 1.3× 72 0.7× 46 1.0× 61 1.4× 13 339
R. F. Bergstrom United States 9 210 0.8× 92 0.8× 78 0.8× 64 1.4× 200 4.7× 15 584

Countries citing papers authored by J. Miceli

Since Specialization
Citations

This map shows the geographic impact of J. Miceli's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J. Miceli with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J. Miceli more than expected).

Fields of papers citing papers by J. Miceli

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J. Miceli. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J. Miceli. The network helps show where J. Miceli may publish in the future.

Co-authorship network of co-authors of J. Miceli

This figure shows the co-authorship network connecting the top 25 collaborators of J. Miceli. A scholar is included among the top collaborators of J. Miceli based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J. Miceli. J. Miceli is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Miceli, J., et al.. (2009). P.4.a.015 Adjunctive pregabalin after partial response to SSRI or SNRI in GAD: results of a double-blind, placebo-controlled trial. European Neuropsychopharmacology. 19. S593–S594. 1 indexed citations
2.
Soaita, Adina, et al.. (2009). 304 A RANDOMIZED, DOUBLE-BLIND, 6-WEEK, DOSE-RANGING STUDY OF PREGABALIN IN SUBJECTS WITH RESTLESS LEGS SYNDROME. Sleep Medicine. 10. S82–S82. 1 indexed citations
3.
Vieta, Eduard, et al.. (2008). Ziprasidone in the treatment of acute mania: a 12-week, placebo-controlled, haloperidol-referenced study. Journal of Psychopharmacology. 24(4). 547–558. 56 indexed citations
4.
Miceli, J., et al.. (2000). Single‐ and multiple‐dose pharmacokinetics of ziprasidone under non‐fasting conditions in healthy male volunteers. British Journal of Clinical Pharmacology. 49(S1). 5–13. 73 indexed citations
5.
6.
Miceli, J., et al.. (2000). The effects of ketoconazole on ziprasidone pharmacokinetics —a placebo‐controlled crossover study in healthy volunteers. British Journal of Clinical Pharmacology. 49(S1). 71–76. 53 indexed citations
7.
Miceli, J., et al.. (2000). The effect of carbamazepine on the steady‐state pharmacokinetics of ziprasidone in healthy volunteers. British Journal of Clinical Pharmacology. 49(S1). 65–70. 64 indexed citations
8.
Shad, Mujeeb U., Sheldon Preskorn, J. Miceli, & Keith D. Wilner. (1999). Use of population pharmacokinetic modeling to characterize intramuscular pharmacokinetics for ziprasidone in schizophrenic patients. Clinical Pharmacology & Therapeutics. 65(2). 171–171. 1 indexed citations
9.
Miceli, J., et al.. (1999). Lack of drug interactions with ziprasidone: An overview. European Neuropsychopharmacology. 9. 264–264. 1 indexed citations
10.
Miceli, J., et al.. (1998). Characterization of the intramuscular pharmacokinetics of ziprasidone in schizophrenic patients. European Psychiatry. 13(S4). 304s–305s. 4 indexed citations
11.
Miceli, J., et al.. (1998). The population pharmacokinetics of intramuscular ziprasidone in healthy and schizophrenic subjects. European Neuropsychopharmacology. 8. S239–S239. 3 indexed citations
12.
Prakash, Chandra, et al.. (1997). Ziprasidone metabolism and cytochrome P450 isoforms. Biological Psychiatry. 42(1). 40S–40S. 2 indexed citations
13.
Wilner, Keith D., et al.. (1996). Anxiolytic effects of ziprasidone, an atypical antipsychotic, compared with diazepam and placebo on subjects prior to undergoing minor dental surgery.. Clinical Pharmacology & Therapeutics. 59(2). 177–177. 1 indexed citations
14.
Zorn, Stevin H., Keith D. Wilner, J. Miceli, et al.. (1996). The preclinical profile of the new antipsychotic, ziprasidone. European Psychiatry. 11. 404s–405s. 1 indexed citations
15.
Miceli, J., et al.. (1996). Single and multiple dose pharmacokinetics of ziprasidone in healthy males. European Psychiatry. 11. 429s–429s. 2 indexed citations
16.
Wilner, Keith D., et al.. (1996). Anxiolytic effects of ziprasidone compared with diazepam and placebo prior to dental surgery. European Neuropsychopharmacology. 6. 117–117. 2 indexed citations
17.
Wilner, Keith D., et al.. (1996). Single and multiple dose pharmacokinetics of ziprasidone in healthy males. European Neuropsychopharmacology. 6. 38–38. 2 indexed citations
18.
Miceli, J., et al.. (1994). The pharmacokinetics of CP-88,059 in healthy male volunteers following oral and intravenous administration. Clinical Pharmacology & Therapeutics. 55(2). 142. 6 indexed citations
19.
20.
Miceli, J., et al.. (1990). Pharmacokinetics and dynamics of furosemide in the newborn piglet.. Journal of Pharmacology and Experimental Therapeutics. 253(3). 1126–1132. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Cara L. Alfaro Breakdown of academic impact, for papers by Sandra Boom Breakdown of academic impact, for papers by Per T. Thyrum Breakdown of academic impact, for papers by Aldo Madia Breakdown of academic impact, for papers by John W. Barnhill Breakdown of academic impact, for papers by Katrin M. Kirschbaum Breakdown of academic impact, for papers by Krishna Talluri Breakdown of academic impact, for papers by M. Ancione Breakdown of academic impact, for papers by E Jaquenoud Sirot Breakdown of academic impact, for papers by R. F. Bergstrom
Rankless by CCL
2026